减肥剂和肝酶升高之间的关联:基于人口的横截面研究
Ye-Jee Kim1, Seo Young Kang2, Mi-Sook Kim3
1Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Scientific reports
|September 22, 2023
概括
减肥剂可能会增加肝酶,特别是在男性和年轻人中. 使用多种类型的这些药物,包括传统药物和补充剂,增加了这种风险,需要进一步调查.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 药物监督 药物监督 药物监督
- 公共卫生 公共卫生
背景情况:
- 体重控制剂的广泛使用需要了解它们的潜在不良影响.
- 之前与这些药物相关的肝酶升高的记录仅限于病例报告.
- 需要人口层面的数据来评估减肥剂与肝酶升高之间的关联.
研究的目的:
- 在大量人群中调查减肥剂使用与肝酶升高之间的关联.
- 为了确定与肝酶升高相关的特定类型的减肥剂.
- 根据性别,年龄和体重指数等人口因素对发现进行分层.
主要方法:
- 使用韩国国家健康和营养检查调查 (KNHANES) 数据 (2013-2019) 进行的横截面研究.
- 包括36259名20岁以上的参与者,没有肝炎,癌症或功能衰竭的病史.
- 用多个逻辑回归模型来分析关联,调整混因素并按性别,年龄和BMI分层.
主要成果:
- 减肥剂的使用与男性的肝酶升高有关 (aOR: 1.36) 和40岁以下的参与者 (aOR: 1.44).
- 体重减轻剂类型的增加与肝酶升高的可能性更高相关 (1剂:aOR 1.31;≥2剂:aOR 1.93).
- 在男性中,传统药物 (aOR: 1.96) 和食补充剂 (aOR: 1.33) 与肝酶升高显著相关.
结论:
- 减肥剂和肝酶升高之间存在关联,特别是在男性中.
- 传统的草药和食补充剂是对男性这种关联的关键贡献者.
- 需要使用更高水平的证据进行进一步的研究来证实这些发现.
相关概念视频
Hepatic Drug Excretion: Influencing Factors
147
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
147
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
691
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
691
Overview of Lipid Metabolism
1.7K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
1.7K
Diseases of the Liver and Gallbladder
614
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
614
Hepatic Drug Clearance: Effect of Protein Binding
230
Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
230


